Gemcitabine in combination with capecitabine compared with gemcitabine combined with erlotinib in locally advanced or metastatic pancreatic cancer

被引：0

作者：

Khatri, P. ^{[1
]}

Kumari, P. ^{[2
]}

Beniwal, S. ^{[3
]}

Samdariya, S. ^{[4
]}

机构：

[1] Acharya Tulsi Canc Hosp & Res Ctr & Allied Hosp, Bikaner, India

[2] Acharya Tulsi Reg Canc Treatment & Res Ctr, Bikaner, India

[3] ATRCTRI, Bikaner, India

[4] AIIMS Jodhpur, Jodhpur, Rajasthan, India

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

RM-028

引用

页码：92 / 92

页数：1

共 50 条

[1] A PILOT TRIAL OF GEMCITABINE IN COMBINATION WITH CAPECITABINE OR ERLOTINIB COMPARED TO GEMCITABINE ALONE IN PATIENTS WITH ADVANCED PANCREATIC CANCER
Cho, J. Y.
Lim, J. Y.
Lee, S. J.
Lee, D. K.
Park, J. S.
Yoon, D. S.
Min, Y. H.
ANNALS OF ONCOLOGY, 2012, 23 : 240 - 240
[2] Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
Lim, Jae Yun
Cho, Jang Ho
Lee, Se Joon
Lee, Dong Ki
Yoon, Dong Sup
Cho, Jae Yong
CANCER RESEARCH AND TREATMENT, 2015, 47 (02): : 266 - 273
[3] Gemcitabine and oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer
All, M.
Carillio, G.
Mazzola, A.
Bagnato, S.
Di Leo, M. G.
Fallica, G.
Anna, Aiello R.
Chiarenza, M.
Caruso, M.
ANNALS OF ONCOLOGY, 2006, 17 : XI52 - XI52
[4] Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer
Kulke, Matthew H.
Blaszkowsky, Lawrence S.
Ryan, David P.
Clark, Jeffrey W.
Meyerhardt, Jeffrey A.
Zhu, Andrew X.
Enzinger, Peter C.
Kwak, Eunice L.
Muzikansky, Alona
Lawrence, Colleen
Fuchs, Charles S.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (30) : 4787 - 4792
[5] Gemcitabine combined with capecitabine compared to gemcitabine with or without erlotinib as first-line chemotherapy in patients with advanced pancreatic cancer: Comparative effectiveness study.
Cho, Jangho
Lim, Jae Yun
Cho, Jae Yong
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[6] Survival Benefit with the Combination of Docetaxel, Gemcitabine and Erlotinib in Advanced and/or Metastatic Pancreatic Cancer Patients
Samelis, Georgios F.
Ekmektzoglou, Konstantinos
Tsiakou, Andriani
Giannakaki, Styliani
Konstadoulakis, Manoussos
HEPATO-GASTROENTEROLOGY, 2011, 58 (110) : 1776 - 1781
[7] Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer:: Results of a GERCOR and GISCAD phase III trial
Louvet, C
Labianca, R
Hammel, P
Lledo, G
Zampino, MG
André, T
Zaniboni, A
Ducreux, M
Aitini, E
Taïeb, J
Faroux, R
Lepere, C
de Gramont, A
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) : 3509 - 3516
[8] A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer
Oh, D.
Lee, K.
Lee, K.
Sohn, C.
Zang, D.
Ryoo, H.
Song, H.
Kim, J.
Bang, Y.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[9] Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results
Semrad, Thomas
Barzi, Afsaneh
Lenz, Heinz-Josef
Hutchins, Irene M.
Kim, Edward J.
Gong, I-Yeh
Tanaka, Michael
Beckett, Laurel
Holland, William
Burich, Rebekah A.
Snyder-Solis, Leslie
Mack, Philip
Lara, Primo N., Jr.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (03) : 518 - 524
[10] Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results
Thomas Semrad
Afsaneh Barzi
Heinz-Josef Lenz
Irene M. Hutchins
Edward J. Kim
I-Yeh Gong
Michael Tanaka
Laurel Beckett
William Holland
Rebekah A. Burich
Leslie Snyder-Solis
Philip Mack
Primo N. Lara
International Journal of Clinical Oncology, 2015, 20 : 518 - 524

← 1 2 3 4 5 →